The stock of Tempest Therapeutics Inc (TPST) has gone up by 8.34% for the week, with a 8.73% rise in the past month and a -29.30% drop in the past quarter. The volatility ratio for the week is 11.13%, and the volatility levels for the past 30 days are 6.61% for TPST. The simple moving average for the last 20 days is 7.85% for TPST stock, with a simple moving average of -35.49% for the last 200 days.
Is It Worth Investing in Tempest Therapeutics Inc (NASDAQ: TPST) Right Now?
The stock has a 36-month beta value of -1.93. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TPST is 3.37M, and at present, short sellers hold a 3.30% of that float. On June 12, 2025, the average trading volume of TPST was 98.41K shares.
TPST) stock’s latest price update
Tempest Therapeutics Inc (NASDAQ: TPST) has seen a decline in its stock price by -15.88 in relation to its previous close of 8.88. However, the company has experienced a 8.34% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-11 that BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale in a registered direct offering of 739,000 shares of its common stock (or common stock equivalents), at an offering price of $6.25 per share of common stock (or common stock equivalent).
Analysts’ Opinion of TPST
Scotiabank gave a rating of “Sector Outperform” to TPST, setting the target price at $13 in the report published on March 14th of the previous year.
TPST Trading at 4.41% from the 50-Day Moving Average
After a stumble in the market that brought TPST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.93% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at TPST starting from Versant Venture Capital VI, L., who proposed sale 387,999 shares at the price of $1.10 back on Aug 12 ’24. After this action, Versant Venture Capital VI, L. now owns shares of Tempest Therapeutics Inc, valued at $426,993 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Tempest Therapeutics Inc, sale 400,000 shares at $1.35 during a trade that took place back on Aug 08 ’24, which means that Versant Venture Capital VI, L. is holding 597,940 shares at $540,040 based on the most recent closing price.
Stock Fundamentals for TPST
Current profitability levels for the company are sitting at:
- -92.57 for the present operating margin
- 0.18 for the gross margin
The net margin for Tempest Therapeutics Inc stands at -92.18. The total capital return value is set at -2.37. Equity return is now at value -282.07, with -117.06 for asset returns.
Based on Tempest Therapeutics Inc (TPST), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -1.97. The debt to equity ratio resting at 1.18. The interest coverage ratio of the stock is -57.16.
Currently, EBITDA for the company is -40.14 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 39.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.70.
Conclusion
To sum up, Tempest Therapeutics Inc (TPST) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
